XML 91 R38.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements - Astellas Agreements - Additional Information (Detail) - Astellas Agreement [Member] - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | 35 Months Ended | 45 Months Ended
--- | --- | --- | --- | --- | ---
Apr. 30, 2006 | Jun. 30, 2005 | Jun. 30, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2010 | Feb. 28, 2009 | Feb. 28, 2009
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received |  |  |  |  |  |  |  |  |  |  | $ 360,100
Japan [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received |  |  |  |  |  |  |  |  |  |  | $ 40,100
Development and regulatory approval milestones |  | $ 117,500 |  |  |  |  |  |  |  |  |
Commercial sales milestone |  | $ 15,000 |  |  |  |  |  |  |  |  |
Additional consideration based on net sales description |  |  |  | Low 20% range |  |  |  |  |  |  |
Clinical development milestones |  |  |  |  |  |  | $ 12,500 |  |  |  |
Milestones revenue |  |  | $ 10,000 | $ 0 | $ 10,000 | $ 0 |  |  |  |  |
Europe [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received |  |  |  |  |  |  |  |  |  | $ 320,000 |
Development and regulatory approval milestones | $ 425,000 |  |  |  |  |  |  |  |  |  |
Additional consideration based on net sales description |  |  |  | Low 20% range |  |  |  |  |  |  |
Clinical development milestones |  |  |  |  |  |  |  | $ 50,000 | $ 40,000 |  |
Milestones revenue |  |  |  | $ 0 | $ 0 | $ 0 |  |  |  |  |
Percentage of joint development costs committed to fund | 50.00% |  |  |  |  |  |  |  |  |  |

X
- Definition The amount of additional consideration based on net sales of product as defined under a collaboration agreement. + References No definition available. + Details
Name: | fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to clinical development under the collaborative agreement. + References No definition available. + Details
Name: | fgen_ClinicalDevelopmentMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_CommercialSalesMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement. + References No definition available. + Details
Name: | fgen_DevelopmentAndRegulatoryApprovalMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs. + References No definition available. + Details
Name: | fgen_PercentageOfFundingForCosts
Namespace Prefix: | fgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |